Hillhurst Biopharmaceuticals, Inc.

Hillhurst Bio Secures $6.3 Million in Grants to Advance Novel Parkinson's Disease Treatment

14 days ago

• Hillhurst Biopharmaceuticals has received $6.3 million in grants, including $2 million from The Michael J. Fox Foundation and $4.3 million from the Farmer Family Foundation in collaboration with Massachusetts General Hospital. • The funding will support a Phase 2a clinical trial evaluating Hillhurst's innovative liquid drug therapy designed to protect against Parkinson's disease progression through cytoprotective pathways. • The 36-participant study, scheduled to begin in early 2025, will assess safety, pharmacokinetics, and biomarkers associated with a 14-day dosing regimen of the novel therapeutic approach.